Novel Pneumocystis Antigens for Seroprevalence Studies

Dora Pungan, Jia Fan, Guixiang Dai, Mst Shamima Khatun, M Dietrich, Kevin J. Zwezdaryk, James E. Robinson, Samuel J. Landry, Jay K. KollsJournal of Fungi 2023 · DOI

TL;DR

This paper identifies novel antigens from Pneumocystis jirovecii, a common cause of pneumonia in young children, by analyzing proteins from infected mice. They found that a fungal glucanase and another protein (PNEG_01454) show promising serological responses in both animal models and human pediatric samples, offering new tools for tracking Pneumocystis exposure.

What Problem Does This Paper Address?

Pneumocystis jirovecii pneumonia (PCP) is a significant health concern, particularly for infants under two years old, and is the most common fungal pneumonia in immunocompromised children. However, studying P. jirovecii is challenging because it cannot be easily cultured in a lab. This limitation hinders the development of reliable methods to track its prevalence (seroprevalence) and how immunity develops over time (seroconversion). Previous serological studies relied on less specific antigens, which could be contaminated with host proteins. The researchers aimed to identify and validate new, specific antigens from P. jirovecii that could be used to overcome these limitations and improve serological diagnostic tools.

Methods

The study employed a multi-pronged approach:

  • Proteomics for Antigen Discovery: They performed untargeted proteomics on bronchoalveolar lavage (BAL) fluid from mice infected with Pneumocystis murina. This technique identifies proteins present in the infected lung environment, potentially revealing key antigens.
  • Bioinformatics and Genome Analysis: Using the available P. murina and P. jirovecii genomes, they prioritized identified proteins for further investigation. A key criterion was conservation across fungal species, suggesting broader applicability.
  • Recombinant Protein Expression: A promising candidate, a fungal $\beta$-1,3-endoglucanase (PNEG_02407), was selected due to its conservation and reported expression in different Pneumocystis life stages. This protein was then produced as a recombinant antigen in Chinese Hamster Ovary (CHO) cells.
  • ELISA for Serological Assays: Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect IgG antibodies against the recombinant glucanase and other Pneumocystis antigens in various sample sets:
  • Murine Model: Sera from P. murina-infected mice were tested to validate antibody responses in a controlled setting.
  • Pediatric Cohorts: Residual blood samples from children (under 18) were analyzed to assess seroprevalence in a relevant human population. This included both a discovery and a validation cohort.
  • Cord Blood: Samples from newborns were tested to assess maternal antibody transfer.
  • Statistical Analysis: Standard statistical methods, including the Mann-Whitney U test and simple linear regression, were used to compare antibody titers and assess correlations.

Datasets

The study utilized the following datasets:

  • Murine BAL Fluid: Collected from Pneumocystis-infected mice for proteomic analysis.
  • Pediatric Blood Samples: Residual serum samples from 133 children (under 18) collected between March and May 2020 from Children's Hospital in New Orleans. These samples were confirmed to be SARS-CoV-2 and HIV negative.
  • Human Cord Blood Samples: Obtained from commercial suppliers (StemCell Technologies) to assess maternal antibody transfer.
  • Existing P. jirovecii and P. murina Genomes: Used for bioinformatic analysis and antigen prioritization.

No new benchmark datasets were introduced; rather, existing sample types were used to validate the identified antigens.

Key Insights and Ideas

  • Proteomics as a powerful tool for antigen discovery: The study successfully leveraged proteomics to identify potential Pneumocystis antigens from infected host material, overcoming the limitations of culturing the organism.
  • Conserved fungal glucanase as a promising serological target: The identification and validation of a $\beta$-1,3-endoglucanase as a conserved antigen across Pneumocystis species is a significant finding, suggesting its utility for broader serological studies.
  • Maternal antibody transfer and early childhood exposure patterns: The detection of maternal IgG to glucanase in cord blood, followed by a nadir in infants and subsequent rise, mirrors the known epidemiological patterns of Pneumocystis exposure in early childhood. This provides strong evidence for the antigen's relevance.
  • Concordance of antibody responses: The strong correlation between IgG responses to glucanase and another previously identified Pneumocystis antigen (PNEG_01454) suggests these antigens may be part of a common immune response to infection.

Key Results

  • Identification of PNEG_02407 (glucanase): Proteomic analysis identified a fungal $\beta$-1,3-endoglucanase as a potential antigen.
  • Recombinant glucanase production: The recombinant P. jirovecii $\beta$-1,3-endoglucanase was successfully expressed and purified.
  • Serological evidence in mice: Infected mice showed IgG responses to whole Pneumocystis antigen, PNEG_01454, and to a lesser extent, glucanase.
  • Pediatric seroprevalence patterns:
    • Maternal IgG to glucanase was detected in cord blood.
  • Infants showed a decline in anti-glucanase IgG between 1-3 months of age, followed by an increase over time.
  • A high concordance (p < 0.0001) was observed between anti-glucanase IgG and anti-PNEG_01454 IgG in pediatric samples.
  • Anti-glucanase IgM titers were low in the first year of life, with increases in older subjects, and did not show a nadir.

Limitations and Future Work

  • Limited epitope analysis: While CD4+ T-cell epitopes were predicted, further experimental validation is needed. Some predicted epitopes were found to be conserved in other commensal or pathogen proteins, limiting their specificity.
  • Need for prospective studies: The study used residual samples. Future work should involve prospective studies to track seroconversion in real-time.
  • Validation in diverse populations: While the pediatric cohort was from New Orleans, validation in broader, diverse populations would strengthen the findings.
  • Further antigen characterization: Investigating other identified antigens from the proteomic screen could yield additional valuable tools.

The authors suggest that these newly identified antigens, particularly the glucanase, hold significant promise as tools for future seroprevalence and seroconversion studies of Pneumocystis infection, especially in vulnerable pediatric populations.

Summary updated

Abstract

<i>Pneumocystis jirovecii</i> is the most common cause of fungal pneumonia in children under the age of 2 years. However, the inability to culture and propagate this organism has hampered the acquisition of a fungal genome as well as the development of recombinant antigens to conduct seroprevalence studies. In this study, we performed proteomics on <i>Pneumocystis</i>-infected mice and used the recent <i>P. murina</i> and <i>P. jirovecii</i> genomes to prioritize antigens for recombinant protein expression. We focused on a fungal glucanase due to its conservation among fungal species. We found evidence of maternal IgG to this antigen, followed by a nadir in pediatric samples between 1 and 3 months of age, followed by an increase in prevalence over time consistent with the known epidemiology of <i>Pneumocystis</i> exposure. Moreover, there was a strong concordance of anti-glucanase responses and IgG against another <i>Pneumocystis</i> antigen, PNEG_01454. Taken together, these antigens may be useful tools for <i>Pneumocystis</i> seroprevalence and seroconversion studies.
BibTeX
@article{pungan2023novel,
  author = {Dora Pungan and Jia Fan and Guixiang Dai and Mst Shamima Khatun and M Dietrich and Kevin J. Zwezdaryk and James E. Robinson and Samuel J. Landry and Jay K. Kolls},
  title = {{Novel Pneumocystis Antigens for Seroprevalence Studies}},
  journal = {Journal of Fungi},
  year = {2023},
  doi = {10.3390/jof9060602},
}
Figure